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1. Introduction
The implantable cardioverter  defibrillator (ICD) is  currently considered the first  therapy
option to protect patients from life-threatening ventricular arrhythmias.  Several random‐
ized studies demonstrated a reduction in total mortality of up to 55% and a reduction in
arrhythmogenic  mortality  of  up  to  76%  in  ICD  recipients.[1-7]  Within  a  time  frame  of
about 20 years, indications for ICD have evolved from a restricted “last resort therapy” to
a secondary and primary preventive therapy. According to HRS/EHRA Expert Consensus
on the Monitoring of Cardiovascular Implantable Electronic Devices [8], incidence of ICD
implantation in the US and Europe in 2007 was 235,000 and 88,000, respectively, with a
upward trend.
Moreover, prevention of sudden cardiac death (SCD) through the ICD is generally consid‐
ered to represent a therapy, which will be needed for the rest of the patient’s life. Howev‐
er,  regarding  ICD  cost-effectiveness  as  well  as  the  potential  risks  of  ICD  therapy  and
subsequent generator changes the question rises if patients without any adequate ICD in‐
tervention  during  the  lifespan  of  their  index  ICD  really  need  further  ICD  protection.
Therefore, the question whether or not to replace an ICD generator at the time of battery
depletion is of great importance not only for the affected patients but also for their physi‐
cians and cost carriers.
This chapter is aimed to give an overview about the currently published data on long-term
benefit of ICD therapy based on the incidence of adequate ICD therapy and in the ratio of
potentially serious complications.
© 2013 Erkapic and Bauernfeind; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Long-term benefit of ICD therapy
2.1. Secondary prevention trials
Already in 1991, Tchou et al.[9] reported in a single center cohort of 184 patients who re‐
ceived an ICD between 1982 and 1989 (84% with ventricular fibrillation (VF) or sustained
ventricular tachycardia (VT), 9% with non-sustained VT (NSVT) and 6% with pre-/syncope)
that the actual risk of receiving an adequate shock by the fifth year after implantation was
69%, with an observed bimodal distribution: high within first year, and rise after four years.
Occurrence of adequate ICD shock was defined as electrocardiographic documentation
(ECG) of sustained VT at the time of shock or if it was preceded by sudden onset of severe
presyncopal symptoms or syncope.
Grimm et al.[10] investigated ICD therapy episodes which occurred for the first time in pa‐
tients who did not require such therapy prior to generator change. This was a prospective sin‐
gle center study enrolling 26 secondary prevention patients (77% with cardiac arrest and 23
with sustained VT) who received their second ICD device 30±9 months after initial ICD implan‐
tation. Notably, at that time patients had epicardial electrodes, and only a single patient had an
ICD generator with the option to memorize endocardialelectrograms. Adequate shocks were
defined as spontaneous ICD discharges preceded by severe symptoms like presyncope or syn‐
cope or documentation of VT/VF by Holter or telemetry monitoring or stored ECG by ICD. Dur‐
ing a mean follow-up period of 21±9 months after ICD generator replacement, ICD therapy was
reported in 13 of 26 patients (50%), classified as adequate in 9 patients (35%).
Dürsch et al.[11] aimed to evaluate retrospectively the necessity of the replacement of ICD
generators in patients without any adequate, spontaneous ventricular arrhythmia episode
during the life-time of the first implanted device. This study, reported in 1998, compared 62
secondary prevention patients (mean follow-up 51 ± 14 months) with an elective generator
replacement due to battery depletion with 151 ICD patients without replacement (follow-up
16.5 ± 11 months). There was a preponderance of male patients (>80%) with a mean left ven‐
tricular ejection fraction (LVEF) of 31% in both groups. In contrast to the study of Grimm et
al. 86% of patients had transveonusendocardial ICD electrodes and 95% of devices (follow‐
ing generator exchange) had the option to memorize endocardial cardiograms. At that time
most of the ICD systems had the capability of antitachycardiac pacing (ATP) prior to ICD
shock delivery. For the total patient group there was a 5 year event-free probability of 23%,
and no differences were found between the two groups. Subanalysis of the replacement
group patients revealed no difference in the probability of adequate ICD therapy occurrence
prior to or after the replacement of the pulse generator. Notably, in 6 of the 62 (10%) pa‐
tients, the first adequate ICD therapy was documented after generator replacement.
Tandri  et  al.[12]  reported in 2006 a  single  center  ICD registry of  1382 patients,  who re‐
ceived their first ICD between 1980 and 2003 (76% men, LVEF 33 ± 11%) with mainly sec‐
ondary  prevention  indication  (77%).  In  787  (57%)  of  these  patients  ICD  therapy
informations were available.  Adequate ICD therapy was determined based either on the
ICD memory or for ICDs without ECG storage capability on the symptoms that preceded
Cardiac Defibrillation80
the shock. During a mean follow-up of 70 ± 51 months 53% of the patients received ade‐
quate ICD therapy, two thirds of them within the first year of implantation. Out of 127 pa‐
tients (16%) without adequate ICD therapy within 5 years following the index generator
implantation, 8%, 20% and 24% of patients experienced adequate ICD therapy after 6, 10
and 15 years of follow-up, respectively.
Data from another single center ICD registry were reported by Koller et al. in 2008.[13] This
registry comprised data of 442 patients with predominantly secondary prevention (59%)
with ischemic (76%) or dilated cardiomyopathy (24%) with a median follow-up of 3.6 years
(max 12.7 years). Adequate ICD therapy of ventricular arrhythmias stored by intracardiace‐
lectrograms had to be confirmed by an experienced electrophysiologist. The cumulative inci‐
dence of any adequate ICD therapy was 52% during a 7-year observation period with a two-
fold higher risk for patients with secondary prevention compared to primary prevention.
Patients without former adequate ICD therapy within 6 years after the first ICD implanta‐
tion had an observed risk of only 6% for adequate ICD intervention in the following 2 years.
Notably, only 35 patients (8%) had follow-up longer than 6 year.
The long-term follow-up of the Leiden Out-of-Hospital Cardiac Arrest Trial (LOHCAT)[14]
was the first prospective single center observational study to assess the rate of mortality and
risk of adequate ICD therapy in patients with secondary prevention. A total of 456 patients
(86% males, mean LVEF 35±14%) with ischemic heart disease and secondary prevention in‐
dication were followed for 54±35 months after ICD implantation. Adequate ICD therapy
was checked by printouts of the ICD memory. During follow-up 22% of the patients died.
The cumulative incidence of adequate ICD therapy at 1, 5, and 8 years was 24, 52 and 61%,
respectively. Independent factors for higher risk of adequate ICD intervention were previ‐
ous VT, history of AF, wide QRS and poor LVEF. No predictive factors for the absence of
ventricular arrhythmia could be identified. Of the 456 patients, 167 (37%) outlived the life-
span of their index ICD and got generator replacement. No data were reported concerning
how many of these patients had no former adequate ICD therapy and/or received the first
adequate ICD Therapy after generator replacement.
The INcidence free SUrvival after ICD Replacement (INSURE)[15] trial was the first pro‐
spective multicenter observational study to evaluate the risk of adequate ATP and/or ICD
shock delivery after elective ICD replacement. A total of 510 unselected ICD-patients with
(48%) and without (52%) former adequate ICD therapy were enrolled in 29 germancenters
from 2002 until 2007 after an average life-span of their first ICD generator of 62±18 months.
After  device  replacement  patients  were  followed every  3  to  6  months  (mean follow-up
22±16 months) until occurrence of an adequate ICD therapy (stored by intracardiacelectro‐
grams and confirmed by an adjudication committee consisting of three experienced electro‐
physiologists),  death,  second generator  replacement  or  until  common study termination
endpoint. The vast majority (86%) of patients had initially been implanted for secondary
prevention of SCD. The cumulative rates of adequate ICD interventions after one, two and
three years following generator replacement were 32.4%, 41.3% and 48.1% in patients with
former adequate ICD therapy and 10.6%, 17.6% and 21.4% in patients without former ade‐
quate ICD therapy, respectively (HR 3.08, CI:  2.15-4.39, p < 0.001) (Figure 2).  In patients
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without former adequate ICD interventions, only advanced NYHA stages were associated
with higher risk of adequate ICD interventions. However, no predictive factors for lower
probability of ICD therapy could be identified in this group.
Author / Study Year N Age(mean y)
Male
(%)
LVEF
(mean%)
ICM
(%)
NICM
(%)
CAD
(%)
no HD
(%)
Tchou et al. 1991 184 61±11 81 37±14 n.r. 17 81 3
Grimm et al. 1993 26 56±15 73 38±15 n.r. 20 65 15
Dürsch et al. 1998 62 58±11 89 31±9 34 66 -
Tandri et al. 2006 1382 62±11 76 33±11 72 28 70 -
Koller et al. 2008 442 63 89 30 76 24 76 -
Borleffs et al. 2008 456 65 86 35±14 100 - 100 -
Van Welsenes et al. 2011 832 63±13 82 37±15 73 n.r. 73 n.r.
Erkapic et al. 2012 510 65±10 83 39±16 37 25 71 38
LVEF: left ventricular ejection fraction; ICM: ischemic cardiomyopathy; NICM: non-ischemic cardiomyopathy; CAD:
coronary artery disease; no HD: no heart disease. n.r.: not reported
Table 1. Baseline characteristics of patients in secondary prevention trials with long-term follow-up
Author / Study Kind of study FU prior 1. ICD
replacement
(mean months)
FU after 1. ICD
replacement
(mean months)
Overall FU
(mean
months)
First adequate ICD therapy
Tchou et al. retro. s.c. 24±19 - - 69% within 5y
Grimm et al. pros. s.c. 30±9 21±19 - 35% within 6y
Dürsch et al. retro. s.c. - - 50±14 77% within 5 y
(thereof 10% after ICD
replacement)
Tandri et al. retro. s.c. 70±51 46±34 - 53% within 5 y
(additional 24% after ICD
replacement)
Koller et al. retro. s.c. - - 43 52% within 7 y
Borleffs et al. pros. s.c. - - 54±35 61% within 8 y
Van Welsenes et al. retro. s.c. 41±34 - - 51% within 5 y
Erkapic et al. pros. m.c. 62±18 22±16 - 21% within 3 y after ICD
replacement
Retro s.c.: retrospective single center-study; pros. s.c.: prospective single center-study; pros. m.c.: prospective multi-
center study; FU: follow-up; y: years.
Table 2. Incidence of adequate ICD therapy according to follow-up time in secondary prevention trials
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2.2. Primary prevention trials
The first trial which tried to provide data on the long-term benefit of ICD therapy in pri‐
mary prevention patients was published in 2008 by Alsheikh-Ali.[16] Patients with prior
myocardial infarction and LVEF ≤35% who received ICD for primary prevention between
1995 and 2005 formed the basis of this retrospective single center analysis. Of 525 predomi‐
nantly male patients, 115 (22%) received adequate ICD therapy during a mean follow-up of
24 months. Patients who survived more than 5 years after ICD implantation without ade‐
quate therapy, the incidence of adequate ICD intervention was 6% after 7 years of follow-up.
These observations were in accordance to the data of Koller et al. who reported the same
incidence for patients with secondary prevention 7 years after ICD implantation. However,
in both studies only 6-8% of patients had follow-up longer than 6 years after first ICD im‐
plantation. No predictive factors for a lower probability of ICD therapy could be identified
in both studies.
The extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation
(MADIT) IITrial was published in 2010.[17] Post-trial mortality data for all study participants
were obtained from the enrolling centers through hospital records and death registries from
2001 until 2009. One-thousand-twenty study patients who survived to trial closure of MADIT II
formed the basis of this study. The primary endpoint was the occurrence of all-cause mortality
during a median follow-up of 7.6 years. Patients who were treated with an ICD showed a signif‐
icant lower risk of death (34%) compared with non-ICD patients. The evident benefit of ICD
therapy continued even in the long-term follow-up of up to 8 years, but only for patients with
single chamber ICD. Patients with a dual chamber ICD (programmed to active DDD-pacing re‐
gardless of conduction abnormalities) and more advanced NYHA class (≥ II) at enrolment, ex‐
perienced a late increase in mortality due to unnecessary right ventricular pacing leading to
progressive heart failure. This observation underlines previous reported data.[18] Regarding
the long-term benefit due to adequate ICD therapy in the extended MADIT II trial, the cumula‐
tive probability of adequate ICD intervention during 8 years of follow-up was 68%. However,
complete information of ICD interrogation during long term follow-up was only available in
109 patients (10,7%) during the post-trial period.
Author / Study Year N Age
(mean y)
Male
(%)
LVEF
(mean%)
ICM
(%)
NICM
(%)
CAD
(%)
Alsheikh-Ali et al. 2008 525 67±11 81 23±7 100 - 100
Goldenberg et al. 2010 630 64±11 85 ≤35 100 - 100
Van Welsenes et al. 2011 1302 63±11 80 29±12 68 32 68
Van Welsenes et al. 2011 114 61±11 80 26±9 59 41 59
LVEF: left ventricular ejection fraction; ICM: ischemic cardiomyopathy; NICM: non-ischemic cardiomyopathy; CAD:
coronary artery disease.
Table 3. Baseline characteristics of patients in primary prevention trials with long-term follow-up
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Author / Study Kind ofstudy FU prior 1. ICD
replacement
(mean months)
FU after 1. ICD
replacement
(mean months)
Overall FU
(mean
months)
First adequate ICD therapy
Alsheikh-Ali et al. retro. s.c. 24±0.4 - - 22% within 7y
Goldenberg et al. retro. m.c. 18 (10-30) n.r. 91 (42-108) 68% within 8y
Van Welsenes et al. retro. s.c. 41±34 - - 37% within 5 y
Van Welsenes et al. retro. s.c. 71±24 25±21 - 14% within 3 y
after ICD replacement
retros.c.: retrospective single center-study; retro. m.c.: retrospective multi-center study; FU: follow-up; y: years.
Table 4. Incidence of adequate ICD therapy according to follow-up time in primary prevention trials
Van Welsenes et al. published two reports in 2011 on long-term follow-up data of a single
center registry of patients with primary and secondary prevention. In the first publica‐
tion[19]they reported all-cause mortality and incidence of adequate ICD therapies in pa‐
tients with primary (61%) and secondary (39%) prevention during the lifetime of the first
implanted ICD. The mean follow-up was 3.4±2.8 years. The cumulative 5-year incidence of
mortality was 25% for primary and 23% for secondary prevention, without reaching statis‐
tifical significance between the two groups. The cumulative 5-year incidence of adequate
ICD therapy (each episode had to be confirmed by a trained electrophysiologist by regard‐
ing the ICD memory/printouts) was 37% for primary and 51% for secondary prevention pa‐
tients (Figure 1).
The second puplication[20] comprised data of 114 patients with exclusively primary preven‐
tion who did not receive adequate therapy during the lifetime of their first ICD generator.
The data were released from the same single center registry and were the first on the topic:
“long-term benefit of ICD-therapy after elective device replacement in primary prevention
patiens”. The single center cohort consisted of mainly ischemic heart disease patients (80%
male, mean age 61±11 years) with a mean LVEF of 26%. After an average life-span of their
first ICD generator of 71±24 months the patients were followed after elective device replace‐
ment for 25±21 months. The cumulative event rate for adequate ICD intervention after re‐
placement increased continuously from 7% after one, 9% after two, to 14% after 3 years
(Figure 3).
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Figure 1. Cumulative incidence of adequate ICD therapies prior elective generator replacement in patients with pri‐
mary and secondary prevention
Figure 2. Cumulative incidence of first adequate ICD therapies (with confidence intervals) after elective device re‐
placement in patients with secondary prevention
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Figure 3. Cumulative incidence of first adequate ICD therapies after elective device replacement in patients with pri‐
mary prevention without prior adequate ICD therapy
3. Challenges of long term ICD therapy
The long-term benefit of ICD therapy has to be evaluated compared to the ratio of potential‐
ly serious complications.
A number of important medical and technological advances in ICD therapies have been
made in the last years which helped to reduce the interventional stress for patients and to
improve their daily safety[14-19]: the introduction of transvenousendocardial leads, subpec‐
toral or subfascial implantation of smaller and more powerful ICD devices, introduction of
diagnostic tools as e.g. monitoring of intrathoracic fluid status, ST segment changes as well
as the introduction of remote home monitoring systems. However, ICD therapy is still asso‐
ciated with significant morbidity and some mortality, especially in long-term follow up.
3.1. Lead failure
One of the major risks of long-term ICD therapy is lead failure, mostly presented as lead
fracture or insulation defect. The annual lead failure rate increases with time and reaches
20% in 10-year old leads.[20] Mechanical stress on leads is the most frequent cause for lead
failure and can be reduced by avoiding the medial subclavian puncture during ICD implan‐
tation (preferred approach is through the cephalic vein or lateral subclavian puncture) and
by avoiding subpectoral device implantation (preferred subfascial pocket, if possible). How‐
ever, careful evaluation required, for the latter may result in pocket complications necessi‐
tating revision operations.
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With the introduction of leads with multilumen design in 1997, lead survival curves initially
improved but were still limited due to missing long-lasting insulation material. Silicon
which is most often used for lead insulation has a good biocompatibility and flexibility, has
a high friction resistance but prone to abrasion of lead insulation material. Even today in a
certain type of ICD lead (RIATA®, SJM, Sylmar, CA) with silicon insulation (removed 2010
from distribution), time-dependent incidence of lead failure of 8-33% were reported.[21-24]
The same lead model with a silicone-polyurethane copolymer (Optim™, SJM, Sylmar, CA)
showed no increased incidence of lead failure, suggesting a better abrasion resistance.[22,25]
Apart from lead insulation material, very small diameter of the ICD lead seemed to be a fur‐
ther risk factor of lead failure.[26] The 6.6 Sprint fidelis® lead (Medtronic, Inc., Minneapolis,
MN) is prone to increased chance of lead fracture due to most likely less stress resistance. In
2008 this high-voltage ICD-lead was removed from the market. Actually, incidence of lead
failure of 17% at 5 years of follow-up is reported for this lead.[27] Therefore, implanted
Sprint fidelis and several Riata lead models should be carefully examined at the time of gen‐
erator replacement.
3.2. Inadequate ICD therapy
Inadequate ICD therapy is a significant clinical issue. In literature it`s reported that 12-30%
of ICD patients receive inadequate ICD therapies, mainly caused by supraventricular tachy‐
cardias, T-wave oversensing and lead failure.[28-30] Such unnecessary ICD therapies are as‐
sociated with increase of posttraumatic disorders as depression and anxiety.[31]It is still a
matter of debate, if aside of morbidity, inadequate ICD shocks also have worse impact on
the outcome of ICD patients.[30,32] However, it is our firm conviction, that the number of
unnecessary ICD therapies triggered by SVTs can be considerably reduced by adequate ICD
programming by an experienced physician. Furthermore, newer ICD algorithms reduced in‐
adequate ICD therapy triggered by T-wave oversensing by 97% while maintaining 100%
sensitivity for detection of true ventricular arrhythmia.[33]The safety, efficacy and perform‐
ance of further new ICD discrimination algorithms is actually evaluated in a prospective
multi-center trial.[34]
Since the introduction of the Lead Integrity Alert™ (LIA) by Medtronic in 2008, inadequate
ICD therapies decreased by up to 50% in patients with fractured Sprint fidelis leads.[35,36]
Moreover, it has been reported that this algorithm has the potential to early detect lead fail‐
ure of the affected Riata family®.[37]
3.3. Risk of ICD generator replacement
Device replacement is associated with significant morbidity and some mortality. Data from
a multicenter prospective registry of 1081 ICD patients who underwent device replacement
(79% males, mean age 64±13 years) showed a complication rate of 4.3%. Major complications
were observed in 2,6%, mostly infections or lead revisions. On multivariate analysis the
presence of advanced Canadian Cardiovascular Society angina class (CCS ≥2), advanced
NYHA stages (≥III), complex device systems (especially cardiac resynchronization systems),
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any previous surgery, and low operator procedure volume were predictive factors for over‐
all complication after ICD replacement. Any complication was associated with an increased
risk of mortality at 45, 90, and 180 days after device replacement with a HR of 8.58, 9.91 and
4.06, respectively (p=0.005 to 0.069).
It is strongly recommended that risks for complications after ICD replacement should not be
underestimated. Even if generator replacement is technically less challenging than a new de‐
vice implantation, it should be preferably performed by experienced operators.
4. Summary/Conclusion
The currently available literature reveals that patients with adequate ICD therapy prior elec‐
tive ICD replacement have approximately 3-fold higher risk to receive adequate ICD interven‐
tion  thereafter  compared  to  patients  without  prior  adequate  ICD  therapy.  However,  a
significant number of patients without adequate ICD therapy prior elective device replace‐
ment will receive adequate ICD intervention thereafter too. In this patient population it is ex‐
pected that approximately every 5th with secondary and every 7th with primary prevention
will receive adequate ICD therapy within 3 years following elective device replacement. Pa‐
tients who present at poor clinical status with more advanced stages of heart failure, especially
with advanced NYHA classes (≥2), as well as patients with secondary prevention indication are
at higher risk for adequate ICD therapy in long-term follow-up. No predictive factors for lower
probability of ICD therapy could be identified for patients without adequate ICD therapy prior
device replacement. Hence, ICD replacement appears still necessary in these patients. Risks of
ICD therapy should not be underestimated but the weight of evidence for long-term benefit
based on the incidence of ventricular arrhythmias with subsequent adequate ICD therapy sup‐
ports the continuing use of ICD therapy for patients with adequate ICD indication. Neverthe‐
less, through an intensive training of physicians in ICD-implantation, device replacement,
programming, and aftercare of ICD patients, as well as the use of newer SVT discrimination
and lead monitoring algorithms the rate of potential risks can be reduced substantially.
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